Protara Therapeutics company info

What does Protara Therapeutics do?
Protara Therapeutics (NASDAQ:TARA) focuses on identifying and advancing transformative therapies for people afflicted with rare and specialty diseases. Their innovative approach aims at developing treatments that can offer significant improvements over existing therapies, primarily concentrating on unmet medical needs. Projects span a range of conditions, with their pipeline including both in-development drugs and potential new therapeutic avenues exploring cutting-edge scientific advances. Objectives are not just limited to drug development but also encompass broadening access to groundbreaking treatments for patients who currently have limited options, underlining Protara's commitment to enhancing health outcomes and ultimately improving quality of life for those they serve.
Protara Therapeutics company media
Company Snapshot

Is Protara Therapeutics a public or private company?

key
Ownership
Public

How many people does Protara Therapeutics employ?

people
Employees
27

What sector is Protara Therapeutics in?

pie chart
Sector
Health Care

Where is the head office for Protara Therapeutics?

location pin
Head Office
New York, United States

What year was Protara Therapeutics founded?

founded flag
Year Founded
2006
What does Protara Therapeutics specialise in?
/Cancer Therapies /Protein Stabilization /TARA-002 Product /Immunostimulatory Therapy /Drug Development /Clinical Trials

What are the products and/or services of Protara Therapeutics?

Overview of Protara Therapeutics offerings
TARA-002, an investigational therapy derived from the OK-432 strain of Streptococcus pyogenes, is designed for the treatment of lymphatic malformations, a rare, non-malignant condition.
Development of advanced drug formulations designed to improve efficacy and reduce side effects for patients with severe medical conditions.
Collaboration with academic and research institutions to discover and develop next-generation treatments for cancer and rare diseases.
Engagement in clinical trials to ensure the safety and efficacy of their therapies, aiming to meet the stringent requirements of regulatory bodies.

Who is in the executive team of Protara Therapeutics?

Protara Therapeutics leadership team
  • Mr. Jesse  Shefferman
    Mr. Jesse Shefferman
    Co-Founder, CEO, President & Director
  • Dr. Jacqueline  Zummo M.B.A., M.P.H., Ph.D.
    Dr. Jacqueline Zummo M.B.A., M.P.H., Ph.D.
    Co-Founder, Senior VP & Chief Scientific Operations Officer
  • Dr. Jathin  Bandari M.D.
    Dr. Jathin Bandari M.D.
    Executive Officer
  • Mr. Patrick  Fabbio M.B.A.
    Mr. Patrick Fabbio M.B.A.
    Chief Financial Officer
  • Ms. Hannah  Fry
    Ms. Hannah Fry
    VP, Principal Accounting Officer & Controller
  • Ms. Justine  O'Malley
    Ms. Justine O'Malley
    Senior Vice President of Investor Relations & Corporate Affairs
  • Ms. Mary J. Grendell
    Ms. Mary J. Grendell
    General Counsel & Corporate Secretary